ID: ALA2179099

Max Phase: Preclinical

Molecular Formula: C22H26FN5O2

Molecular Weight: 411.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@H]1CN(Cc2ccc(F)cc2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1

Standard InChI:  InChI=1S/C22H26FN5O2/c1-14-11-27(12-15-2-4-16(23)5-3-15)13-19(14)20-25-21-18(22(29)26-20)10-24-28(21)17-6-8-30-9-7-17/h2-5,10,14,17,19H,6-9,11-13H2,1H3,(H,25,26,29)/t14-,19-/m1/s1

Standard InChI Key:  GGDJPBJMQBKBTC-AUUYWEPGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 411.48

Molecular Weight (Monoisotopic): 411.2071

AlogP: 2.85

#Rotatable Bonds: 4

Polar Surface Area: 76.04

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.20

CX Basic pKa: 8.09

CX LogP: 1.42

CX LogD: 0.87

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.71

Np Likeness Score: -1.36

References

1. Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S..  (2012)  Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.,  55  (21): [PMID:22780914] [10.1021/jm3007799]

2. Fjelbye K, Marigo M, Clausen RP, Jørgensen EB, Christoffersen CT, Juhl K..  (2018)  Elucidation of fluorine's impact on pK_a and in vitro Pgp-mediated efflux for a series of PDE9 inhibitors.,  9  (5): [PMID:30108979] [10.1039/C8MD00114F]

Source

Source(1):

• Scientific Literature